Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 8/20 | 0.44 |
| ▸ | SLC5A7 | Q9GZV3 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459152 | 0.99 | IGF1R (0.43) | IGF1RSLC5A7HRH3HTTSMN1; SMN2 | |
| SCHEMBL4458522 | 0.92 | IGF1R (0.45) | IGF1RSLC5A7HRH3 | |
| SCHEMBL4467729 | 0.87 | IGF1R (0.42) | IGF1RHRH3SMN1; SMN2KDM4E | |
| SCHEMBL4459206 | 0.82 | PTPN1 (0.44) | IGF1R | |
| SCHEMBL4459340 | 0.81 | PTPN1 (0.43) | IGF1R | |
| SCHEMBL4462239 | 0.79 | IGF1R (0.44) | IGF1RSLC5A7 | |
| SCHEMBL4469451 | 0.76 | EPHX2 (0.33) | IGF1R | |
| SCHEMBL4462384 | 0.75 | IGF1R (0.40) | IGF1RSLC5A7 | |
| SCHEMBL4458966 | 0.70 | IGF1R (0.44) | IGF1R | |
| SCHEMBL4461033 | 0.68 | EPHX2 (0.34) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |